Lu Wang

840P Famitinib malate plus camrelizumab for recurrent platinum-resistant ovarian/fallopian tube/primary peritoneal cancer and advanced cervical cancer: An open-label, multicenter phase II study

G. Lou, Xuehao Wang, X. Wu, 2020 .

EPCT-15. THE REMIND TRIAL: MULTI-ANTIGEN TARGETED T CELLS FOR PEDIATRIC CNS TUMORS

N. Zhang, P. Hanley, C. Bollard, 2020, Neuro-Oncology.